Abstract
Neoadjuvant treatment with immune checkpoint inhibitors (ICI) induces high pathologic response rates with prolonged relapse-free survival. A subset of patients (pts), however, do not respond, which necessitates new additional treatments. Domatinostat (DOM) inhibits pathways relevant for proliferation, differentiation, and metastasis of tumor cells, and preclinical models show promising results when combined with ICI. As a secondary study of the DONIMI trial, we evaluated health-related quality of life (HRQoL) in pts with stage III cutaneous or unknown primary melanoma and high interferon-gamma (IFN-γ) signature (sig).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
